Abstract
Background and aims
Non-small cell lung cancer (NSCLC) is the leading cause of cancer mortality worldwide. As CUGBP1 may also play a great role in tumor genesis and deterioration, the purpose of this study was to detect the expression of CUGBP1 mRNA and CUGBP1 and assess the prognostic significance of CUGBP1 in NSCLC.
Methods
Expression of CUGBP1 mRNA and CUGBP was detected by Semi-quantitative PCR and Immunohistochemistry, respectively, from 57 NSCLC patients. The percentage of CUGBP1 mRNA and CUGBP1 expression was correlated with clinical characteristics using χ 2 test. The prognostic significance was assessed by univariate and multivariate analyses in the Cox hazard model.
Results
The expression of CUGBP1 mRNA and CUGBP1 was over-expressed in cancer group and was correlated with TNM stage and Differentiation. By both univariate and multivariate survival analyses, CUGBP1 expression (P = 0.0074, HR = 3.701, 95 % CI 1.420–9.648), TNM-stage (HR = 4.043, 95 % CI 2.098–7.794) and age (HR = 3.207, 95 % CI 1.544–6.664) were noted to be independent indicators of a shorter postsurgical survival.
Conclusions
The expression of CUGBP1 independently predicted a shorter postsurgical survival in NSCLC.
Similar content being viewed by others
References
Kang S, Koh ES, Vinod SK, Jalaludin B (2012) Cost analysis of lung cancer management in South Western Sydney. J Med Imaging Radiat Oncol 56(2):235–241
Ciervide R, Dhage S, Guth A, Shapiro RL, Axelrod DM, Roses DF et al (2012) Five year outcome of 145 patients with ductal carcinoma in situ (DCIS) after accelerated breast radiotherapy. Int J Radiat Oncol Biol Phys 83(2):e159–e164
Oji Y, Kitamura Y, Kamino E, Kitano A, Sawabata N, Inoue M et al (2009) WT1 IgG antibody for early detection of nonsmall cell lung cancer and as its prognostic factor. Int J Cancer 125(2):381–387
Ward AJ, Rimer M, Killian JM, Dowling JJ, Cooper TA (2010) CUGBP1 overexpression in mouse skeletal muscle reproduces features of myotonic dystrophy type 1. Hum Mol Genet 19(18):3614–3622
Koshelev M, Sarma S, Price RE, Wehrens XH, Cooper TA (2010) Heart-specific overexpression of CUGBP1 reproduces functional and molecular abnormalities of myotonic dystrophy type 1. Hum Mol Genet 19(6):1066–1075
Mulders SA, van den Broek WJ, Wheeler TM, Croes HJ, van Kuik-Romeijn P, de Kimpe SJ et al (2009) Triplet-repeat oligonucleotide-mediated reversal of RNA toxicity in myotonic dystrophy. Proc Natl Acad Sci USA 106(33):13915–13920
Garbarino-Pico E, Green CB (2007) Posttranscriptional regulation of mammalian circadian clock output. Cold Spring Harb Symp Quant Biol 72:145–156
Zheng Y, Miskimins WK (2011) CUG-binding protein represses translation of p27Kip1 mRNA through its internal ribosomal entry site. RNA Biol 8(3):365–371
Zhang L, Lee JE, Wilusz J, Wilusz CJ (2008) The RNA-binding protein CUGBP1 regulates stability of tumor necrosis factor mRNA in muscle cells: implications for myotonic dystrophy. J Biol Chem 283(33):22457–22463
Andrews J, Yeh P, Pao W, Horn L (2011) Molecular predictors of response to chemotherapy in non-small cell lung cancer. Cancer J 17(2):104–113
Pelosi G, Sonzogni A, Viale G (2010) The classification of lung carcinoma: time to change the morphology-based approach? Int J Surg Pathol 18(3):161–172
Cui YH, Xiao L, Rao JN, Zou T, Liu L, Chen Y et al (2012) miR-503 represses CUG-binding protein 1 translation by recruiting CUGBP1 mRNA to processing bodies. Mol Biol Cell 23(1):151–162
Arnal-Estape A, Tarragona M, Morales M, Guiu M, Nadal C, Massague J et al (2010) HER2 silences tumor suppression in breast cancer cells by switching expression of C/EBPss isoforms. Cancer Res 70(23):9927–9936
Rattenbacher B, Beisang D, Wiesner DL, Jeschke JC, von Hohenberg M, St Louis-Vlasova IA et al (2010) Analysis of CUGBP1 targets identifies GU-repeat sequences that mediate rapid mRNA decay. Mol Cell Biol 30(16):3970–3980
Timchenko NA, Patel R, Iakova P, Cai ZJ, Quan L, Timchenko LT (2004) Overexpression of CUG triplet repeat-binding protein, CUGBP1, in mice inhibits myogenesis. J Biol Chem 279(13):13129–13139
Varella-Garcia M, Mitsudomi T, Yatabe Y, Kosaka T, Nakajima E, Xavier AC et al (2009) EGFR and HER2 genomic gain in recurrent non-small cell lung cancer after surgery: impact on outcome to treatment with gefitinib and association with EGFR and KRAS mutations in a Japanese cohort. J Thorac Oncol 4(3):318–325
Thorsteinsson H, Jonsson S, Alfredsson H, Isaksson HJ, Gudbjartsson T (2009) Results of pneumonectomy for non-small cell lung cancer in Iceland. Laeknabladid 95(12):823–829
Hespanhol V, Queiroga H, Magalhaes A, Santos AR, Coelho M, Marques A (1995) Survival predictors in advanced non-small cell lung cancer. Lung Cancer 13(3):253–267
Koo HK, Jin SM, Lee CH, Lim HJ, Yim JJ, Kim YT et al (2011) Factors associated with recurrence in patients with curatively resected stage I-II lung cancer. Lung Cancer 73(2):222–229
Dediu M, Crisan E, Radut M, Tarlea A, Median D, Alexandru A et al (2009) The favorable prognostic significance of atelectasis in patients with advanced non-small cell lung cancer: results of a prospective observational study. Lung Cancer 63(2):271–276
Dundar E, Oner U, Peker BC, Metintas M, Isiksoy S, Ak G (2008) The significance and relationship between mast cells and tumour angiogenesis in non-small cell lung carcinoma. J Int Med Res 36(1):88–95
Wang GS, Kuyumcu-Martinez MN, Sarma S, Mathur N, Wehrens XH, Cooper TA (2009) PKC inhibition ameliorates the cardiac phenotype in a mouse model of myotonic dystrophy type 1. J Clin Invest 119(12):3797–3806
Hoody DW, Beckett CF, Zielenski C, Moore GD (2011) Quality of drug information database research for clinical decision support. Int J Clin Pharm 33(4):599–602
Othman M, Falcon BJ, Kadir R (2010) Global hemostasis in pregnancy: are we using thromboelastography to its full potential? Semin Thromb Hemost 36(7):738–746
Xiao H, Ding J, Gao S, Yang S, Huang Y (2011) Never smokers with lung cancer: analysis of genetic variants. Asian Pac J Cancer Prev 12(10):2807–2809
Grutters JP, Pijls-Johannesma M, Ruysscher DD, Peeters A, Reimoser S, Severens JL et al (2010) The cost-effectiveness of particle therapy in non-small cell lung cancer: exploring decision uncertainty and areas for future research. Cancer Treat Rev 36(6):468–476
Chhatwani L, Cabebe E, Wakelee HA (2009) Adjuvant treatment of resected lung cancer. Proc Am Thorac Soc 6(2):194–200
Acknowledgments
This article was written for a project financed by a grant of Shandong Excellent Young Scientist Research Award Fund Project (BS2010YY013), Shandong Tackle Key Problems in Science and Technology (2010GSF10245). Wenjie Jiao and Ruyong Yao designed the research; Mingzhao Wang and Yongjie Wang carried out the studies; Yiren Luo and Yandong Zhao discussed the results and analyzed data; Jinpeng Zhao wrote the paper. All authors read and approved the final manuscript.
Conflict of interest
The authors declare no conflict of interest.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Jiao, W., Zhao, J., Wang, M. et al. CUG-binding protein 1 (CUGBP1) expression and prognosis of non-small cell lung cancer. Clin Transl Oncol 15, 789–795 (2013). https://doi.org/10.1007/s12094-013-1005-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12094-013-1005-5